Akero Therapeutics (AKRO) PT Raised to $51 at Canaccord Genuity
Tweet
Share
E-mailGet Alerts AKRO Hot Sheet
Price: $54.74 --0%
Rating Summary:
12 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Rating Summary:
12 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Join SI Premium – FREE
Canaccord Genuity analyst Edward Nash raised the price target on Akero Therapeutics (NASDAQ: AKRO) to $51.00 (from $36.00) while maintaining a Buy rating.
You May Also Be Interested In
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
- Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
- Jenoptik AG (JEN:GR) PT Raised to EUR48 at Berenberg
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
